IL6 and plasma cell myeloma: IL-6 is a cytokine that is considered a significant survival factor in MM23 as demonstrated by in vitro and in vivo studies.24 The present study aimed to examine whether the drug combination could abrogate IL-6-mediated cell growth in myeloma.